Hepatocellular carcinoma (HCC, also called hepatoma) is a primary cancer of the liver. Most cases of HCC are secondary to either a viral hepatitis or cirrhosis.
The U.S. Food and Drug Administration (FDA) approves Incivek for hepatitis C – The U.S. Food and Drug Administration approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies.
Obesity comes with plenty of health risks, but there’s one that’s perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. – Epidemiological studies indicate that being overweight or obese is associated with increased cancer risk. The most dramatic effect of obesity on cancer risk has been noted for a common form of liver cancer called hepatocellular carcinoma or HCC.
Anticancer drug Nexavar raised survival period in inoperable hepatocellular carcinoma patients suffering from this kind of liver cancer. – The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.
